The National Cancer Institute's (NCI) Clinical Trials Cooperative Group Program has played a key role in developing new and improved cancer therapies. However, the program is falling short of its potential, and the IOM recommends changes that aim to transform the Cooperative Group Program into a dynamic system that efficiently responds to emerging scientific knowledge; involves broad cooperation of stakeholders; and leverages evolving technologies to provide high-quality, practice-changing research.
Table of Contents
|Overview of Conclusions and Recommendations||5-40|
|2 The Science of Developing Cancer Therapy||77-120|
|3 Operations, Oversight, and Funding of Cancer Clinical Trials||121-190|
|4 Physician and Patient Participation in Cancer Clinical Trials||191-234|
|Appendix A: Previous and Ongoing Analyses Undertaken by NCI||235-258|
|Appendix B: Committee Member and Staff Biographies||259-274|
The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:
For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.
For information on how to request permission to translate our work and for any other rights related query please click here.
For questions about using the Copyright.com service, please contact:
Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
Loading stats for A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program...